Table 3. Overview of prognosis, disease response and complications of included studies.
| Study | OS | PFS | Complication | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Median (months) | 12-month rate | Median (months) | 6-month rate | Grade | Neutropenia | Hypertension | ||||
| 3–4 | 5 | |||||||||
| Horn 2009 | 10.9 | 38.1 | 4.7 | 30.2 | 47 | 2 | 37 | 5 | ||
| Spigel 2009 | 12.1 | 51 | 9.13 | 76 | 74 | 1 | 20 | 0 | ||
| Ready 2011 | 11.6 | 43.8 | 7 | 63 | 41 | 3 | 17 | 6 | ||
| Spigel 2011 | 9.4 | 32.4 | 5.45 | 40.3 | 36 | 2 | 18 | 3 | ||
| Mountzio 2012 | 6.3 | 26.7 | - | 33 | 19 | 0 | 5 | 0 | ||
| Spigel 2013 | 7.4 | 18 | 4.02 | 22 | 71 | 3 | 14 | 0 | ||
| Pujol 2015 | 11.1 | 59.5 | 5.3 | 34.4 | 54 | 3 | 15 | 2 | ||
| Trafalis 2016 | 6 | 3.6 | 3 | 3.6 | 8 | 0 | 2 | 0 | ||
| Tiseo 2017 | 9.8 | 25 | 6.7 | 57.4 | 52 | 0 | 44 | 6 | ||
OS, overall survival; PFS, progression-free survival.